Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income from Continuing Operations: 2009-2025

Historic Income from Continuing Operations for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $5.9 million.

  • Gyre Therapeutics' Income from Continuing Operations rose 107.84% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 112.80%. This contributed to the annual value of $16.9 million for FY2024, which is 119.58% up from last year.
  • Per Gyre Therapeutics' latest filing, its Income from Continuing Operations stood at $5.9 million for Q3 2025, which was up 276.65% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Income from Continuing Operations ranged from a high of $51.6 million in Q2 2022 and a low of -$101.8 million during Q4 2023.
  • For the 3-year period, Gyre Therapeutics' Income from Continuing Operations averaged around -$5.3 million, with its median value being $3.8 million (2023).
  • In the last 5 years, Gyre Therapeutics' Income from Continuing Operations crashed by 453.20% in 2021 and then skyrocketed by 359.09% in 2022.
  • Quarterly analysis of 5 years shows Gyre Therapeutics' Income from Continuing Operations stood at -$20.3 million in 2021, then slumped by 41.75% to -$28.8 million in 2022, then plummeted by 253.66% to -$101.8 million in 2023, then surged by 99.57% to -$433,000 in 2024, then surged by 107.84% to $5.9 million in 2025.
  • Its Income from Continuing Operations was $5.9 million in Q3 2025, compared to $1.6 million in Q2 2025 and $3.7 million in Q1 2025.